XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
Ekta Patel(Xilio Therapeutics (United States)), Carl Uli Bialucha(Xilio Therapeutics (United States))
Cited by 9
Related Papers
No related papers found
Powered by citation graph analysis